John Noseworthy - Merck Independent Director

<div class='circular--portrait' style='background:#008000;color: #f8f8f8;font-size:3em;padding-top: 38px;;'>MRK</div>
MRK -- USA Stock  

Report: 31st of July 2020  

Dr. John H. Noseworthy, M.D. is Independent Director of the Company. Dr. Noseworthy, the Board considered his extensive and distinct expertise in academia, science and medicine relevant to the pharmaceutical industry and the Companys research and development initiatives, including his positions as President and CEO of Mayo Clinic and Professor of Neurology, Mayo Clinic College of Medicine Science. In addition, his past experiences leading controlled clinical trials, as well as his extensive operational and management experience of a largescale medical organization provide him with a deep understanding of the complexities of the U.S. healthcare delivery system and policy environment.
Age: 66  Director Since 2017      
908 735-1500

John Noseworthy Latest Insider Activity

Merck Management Efficiency

Merck Inc has Return on Asset of 11.76 % which means that on every $100 spent on asset it made $11.76 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 37.55 %, implying that it generated $37.55 on every 100 dollars invested. Merck management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Merck Return on Investment is increasing as compared to previous years. The last year's value of Return on Investment was reported at 22.30. The current Return on Average Assets is estimated to increase to 0.13, while Return on Average Equity is estimated to decrease to 0.29. Merck Total Assets Per Share are decreasing as compared to previous years. The last year's value of Total Assets Per Share was reported at 33.24. The current Net Current Assets as percentage of Total Assets is estimated to increase to 6.40, while Revenue to Assets are estimated to decrease to 0.48. The current Total Liabilities is estimated to increase to about 61.3 B. The current Current Liabilities is estimated to increase to about 22.3 B
The company has 28 B in debt with debt to equity (D/E) ratio of 1.06, which is OK given its current industry classification. Merck Inc has a current ratio of 1.1, demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Robert BertoliniBristol Myers Squibb
Jennifer DoudnaJohnson Johnson
Anne MulcahyJohnson Johnson
Kathi SeifertEli Lilly And
Ronald WilliamsJohnson Johnson
Anna LluchGrifols S A
Nazneen RahmanAstrazeneca PLC
Charles PrinceJohnson Johnson
Roy AndersonGlaxoSmithKline PLC
Christopher ToveyGW Pharmaceuticals Plc
Nuria LapenaGrifols S A
Dinesh PaliwalBristol Myers Squibb
Vicki SatoBristol Myers Squibb
Nicholas MooreGilead Sciences
Marvinder BangaGlaxoSmithKline PLC
Matthew EmmensBristol Myers Squibb
Dimitri AzarNovartis AG
Hubert JolyJohnson Johnson
Philip HamptonGlaxoSmithKline PLC
Sherilyn McCoyAstrazeneca PLC
Thomas LynchGW Pharmaceuticals Plc

Company Summary

It operates through Pharmaceutical and Animal Health segments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 71000 people.Merck Company (MRK) is traded on BATS Exchange in USA. It is located in 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States and employs 71,000 people. Merck Company was previously known as Merck Co and was traded on BATS Exchange under the symbol SGP. Merck is listed under Pharmaceutical Products category by Fama And French industry classification.

Merck Inc Leadership Team

Thomas Glocer, Independent Director
Craig Thompson, Independent Director
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Rochelle Lazarus, Independent Director
Christine Seidman, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Kathy Warden, Independent Director
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Adele Ambrose, Senior Vice President Chief Communications Officer
Joseph Romanelli, IR Contact Officer
Mirian GraddickWeir, Executive Vice President - Human Resources
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Leslie Brun, Lead Independent Director
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Inge Thulin, Independent Director
Pamela Craig, Independent Director
Patricia Russo, Independent Director
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Franklin Clyburn, Executive Vice President Chief Commercial Officer
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Robert Kidder, Independent Director
Thomas Cech, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Clark Golestani, CIO and Executive VP
William Harrison, Lead Independent Director
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
Frank Clyburn, Executive Vice President, Chief Commercial Officer

Stock Performance Indicators

Did you try this?

Run Positions Ratings Now


Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page